SPRC - SciSparc Corp Total Debt to Capital

The available price action vector for the debt-to-equity ratio of SciSparc Ltd (SPRC) is 0.68. SciSparc Ltd (SPRC) is implementing environmental ESG principles into the synthesis of CNS agents while adhering to testing ethics. The business possesses high expansion potential due to unique formulas with low-cost mass production. Currently, SciSparc Ltd (SPRC) is developing an R&D pipeline of innovative cannabinoid drugs for the therapy of Tourette syndrome.

The indicator is calculated as the ratio of total liabilities to net equity, allowing for a real-time assessment of financial leverage dynamics and balance sheet sensitivity to new loans. A decrease in the debt-to-equity ratio confirms the funding stability of SciSparc Ltd. R&D complexes and laboratory facilities, ensuring the absence of cash flow gaps while strictly adhering to contract manufacturing schedules.